Revlimid (lenalidomide) is a brand-name oral capsule that’s prescribed for certain types of myeloma, lymphoma, and anemia. As with other drugs, Revlimid can cause side effects, such as skin rash and ...
TEL AVIV, Israel & PARSIPPANY, N.J.--(BUSINESS WIRE)--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a first generic ...
Combination tafasitamab, lenalidomide, and rituximab is a recommended second-line regimen based on the phase 3 InMIND trial. The clinical data supporting the addition of tafasitamab to lenalidomide ...
A phase 3 clinical trial evaluating the use of lenalidomide (Revlimid, Celgene) in 450 patients with chronic lymphocytic leukemia (CLL) has been stopped. The trial was exploring CLL as a new ...
Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...
Patients receiving the tafasitamab combination achieved a median PFS of 22.4 months, compared with 13.9 months for patients receiving placebo with lenalidomide and rituximab. This represents a 57% ...
RIO DE JANEIRO — The addition of daratumumab to lenalidomide maintenance therapy following autologous stem cell transplant (ASCT) significantly improves rates of achieving minimal residual disease ...
A new study conducted by researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore has uncovered a key mechanism behind lenalidomide resistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results